Literature DB >> 16644110

Genetic and epigenetic analysis of the TIMP-3 gene in ovarian cancer.

Mira C P Liu1, David Y H Choong, Christine S F Hooi, Louise H Williams, Ian G Campbell.   

Abstract

Chromosome 22q shows a high frequency of loss of heterozygosity (LOH) in ovarian cancers suggesting the existence of one or more important tumor suppressor genes (TSGs). The tissue inhibitor of metalloproteinase-3 (TIMP-3) is a plausible TSG candidate since it is often encompassed within these regions of LOH. TIMP-3 has not previously been investigated for somatic mutations or promoter hypermethylation in ovarian cancer. We analyzed 65 ovarian cancers for both somatic genetic mutations and TIMP-3 promoter hypermethylation. Screening of all coding exons of TIMP-3 did not reveal any somatic genetic mutations and only 1/65 showed TIMP-3 methylation. Our data indicate that inactivation of TIMP-3 by somatic mutation or promoter hypermethylation is rare in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644110     DOI: 10.1016/j.canlet.2006.03.024

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

1.  Epigenetic regulation of matrix metalloproteinases and their collagen substrates in cancer.

Authors:  Andrei V Chernov; Alex Y Strongin
Journal:  Biomol Concepts       Date:  2011-06

2.  Gene regulatory network inference: evaluation and application to ovarian cancer allows the prioritization of drug targets.

Authors:  Piyush B Madhamshettiwar; Stefan R Maetschke; Melissa J Davis; Antonio Reverter; Mark A Ragan
Journal:  Genome Med       Date:  2012-05-01       Impact factor: 11.117

3.  The Association of BRAF V600E Mutation With Tissue Inhibitor of Metalloproteinase-3 Expression and Clinicopathological Features in Papillary Thyroid Cancer.

Authors:  Maryam Zarkesh; Azita Zadeh-Vakili; Fereidoun Azizi; S Ahmad Fanaei; Forough Foroughi; Mehdi Hedayati
Journal:  Int J Endocrinol Metab       Date:  2018-02-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.